within Pharmacolibrary.Drugs.ATC.J;

model J01DC11
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0012333333333333332,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0075,
    k12             = 8.6,
    k21             = 8.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DC11</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ceforanide is a second-generation cephalosporin antibiotic that has been used for the treatment of various bacterial infections, including respiratory tract, urinary tract, skin, and soft tissue infections. It is administered parenterally (intravenous or intramuscular routes). Ceforanide is no longer widely used and is not approved in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration.</p><h4>References</h4><ol><li><p>Ripa, S, et al., &amp; Pfeffer, M (1982). Pharmacokinetics of ceforanide. <i>Antimicrobial agents and chemotherapy</i> 21(2) 323–326. DOI:<a href=\"https://doi.org/10.1128/AAC.21.2.323\">10.1128/AAC.21.2.323</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7073268/\">https://pubmed.ncbi.nlm.nih.gov/7073268</a></p></li><li><p>Smyth, RD, et al., &amp; Hottendorf, GH (1979). Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin. <i>Antimicrobial agents and chemotherapy</i> 16(5) 615–621. DOI:<a href=\"https://doi.org/10.1128/AAC.16.5.615\">10.1128/AAC.16.5.615</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/526003/\">https://pubmed.ncbi.nlm.nih.gov/526003</a></p></li><li><p>DiPiro, JT, et al., &amp; Rissing, JP (1985). Intraoperative ceforanide pharmacokinetics and protein binding. <i>Antimicrobial agents and chemotherapy</i> 27(4) 487–490. DOI:<a href=\"https://doi.org/10.1128/AAC.27.4.487\">10.1128/AAC.27.4.487</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/4004190/\">https://pubmed.ncbi.nlm.nih.gov/4004190</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DC11;
